Kedhbs (Human Hepatitis B Immunoglobulin)

Kedhbs is an immunoglobulin that provides passive immunity against hepatitis B virus.

• Post‑exposure prophylaxis: prevents hepatitis B infection after known or suspected exposure.
• Prevention after perinatal exposure: administered to newborns of hepatitis B‑positive mothers to reduce mother‑to‑child transmission.
• Immunoprophylaxis for non‑immune individuals: provides immediate protection to persons lacking hepatitis B antibodies who are at risk of infection.

• Human Hepatitis B Immunoglobulin supplies exogenous anti‑HBV antibodies that bind to circulating hepatitis B virus particles, neutralizing them and blocking entry into hepatocytes. This passive immunity reduces viral replication and limits the spread of infection during the critical period before the host's own immune response can develop.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the intramuscular site.
• Redness or swelling: localized erythema or edema at the injection area.
• Fever: transient low‑grade temperature elevation.
• Headache: mild headache occurring within hours after administration.
• Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Serum sickness-like reaction: fever, rash, arthralgia occurring days after dosing.
• Aseptic meningitis: rare inflammation of the meninges without infection.
• Thrombocytopenia: low platelet count leading to bleeding risk.
• Hemolysis: destruction of red blood cells causing anemia.

Before administering Kedhbs, consider the following precautions:

• Assess hepatitis B serology: confirm lack of protective antibodies before use.
• Screen for hypersensitivity: avoid in patients with known allergy to human immunoglobulins.
• Use with caution in immunocompromised patients: monitor for altered efficacy.
• Avoid in individuals with IgA deficiency and anti‑IgA antibodies: risk of severe reactions.
• Monitor for signs of infection: observe for fever or systemic symptoms post‑injection.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hepatitis B Immunoglobulin may interact with other agents as follows:

Major Interactions (Avoid)

• Live vaccines: concurrent administration may reduce vaccine efficacy.
• Serologic testing: may interfere with hepatitis B surface antigen assays, leading to false‑positive results.

Moderate Interactions (Monitor Closely)

• Anticoagulants: increased risk of bleeding at injection site.
• Immunosuppressants: potential alteration of passive immunity duration.
• Other immunoglobulin products: cumulative antibody load may increase risk of adverse reactions.